Proteomics & Protein Research

Headed by Gordon Mills and Rehan Akbanie, the MD Anderson GCC will use reverse phase protein arrays to investigate tumor tissue from a variety of NCI projects.

The effort will use Biognosys' HRM method and is part of a move at Biodesix to add a "hypothesis-based approach" to its biomarker work, a company official said.

The funds will support a multi-center clinical study investigating the test's usefulness in diagnosing elderly patients with lower respiratory tract infections.

The upgrade follows four consecutive quarters of above-industry-average revenue growth, driven by the biopharma end market, and the addition of a new CEO.

The collaboration is focused on using Biognosys' HRM mass spec technology to facilitate Biodesix's companion diagnostic work.